IRIS
BRILLANTI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.280
EU - Europa 2.247
AS - Asia 426
SA - Sud America 9
AF - Africa 3
AN - Antartide 1
Totale 5.966
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.257
GB - Regno Unito 677
IE - Irlanda 529
IT - Italia 251
CN - Cina 248
FR - Francia 203
RU - Federazione Russa 203
UA - Ucraina 137
SE - Svezia 117
SG - Singapore 116
DE - Germania 42
FI - Finlandia 42
CA - Canada 21
TR - Turchia 19
VN - Vietnam 19
BE - Belgio 12
BR - Brasile 7
ES - Italia 7
IR - Iran 7
PT - Portogallo 7
CH - Svizzera 5
HK - Hong Kong 4
JP - Giappone 4
BD - Bangladesh 2
CZ - Repubblica Ceca 2
HR - Croazia 2
IN - India 2
MX - Messico 2
NL - Olanda 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
GS - Georgia del Sud e Isole Sandwich Australi 1
ID - Indonesia 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 5.966
Salva come PNG Salva come JPEG
Città #
Southend 638
Fairfield 583
Dublin 523
Ashburn 325
Chandler 324
Woodbridge 269
Seattle 232
Wilmington 203
Cambridge 200
Jacksonville 175
Houston 173
Princeton 132
Ann Arbor 107
Singapore 80
Siena 74
Beijing 59
Nanjing 49
Helsinki 40
San Mateo 36
San Diego 35
Boardman 25
Moscow 23
Paris 21
Shanghai 21
Dong Ket 18
Dearborn 17
Izmir 17
London 16
Hebei 15
Florence 11
Rome 11
Shenyang 11
Brussels 10
Milan 10
Nanchang 9
Palermo 9
Jiaxing 8
New York 8
Tianjin 8
Catania 7
Changsha 7
Norwalk 7
Isfahan 6
Lambeth 6
San Francisco 6
Toronto 6
Chur 5
Fremont 5
Naples 5
Santa Clara 5
Santos 5
Turin 5
Waterloo 5
Bari 4
Haikou 4
Kunming 4
Lanzhou 4
Lisbon 4
Ottawa 4
Somma Vesuviana 4
Falconara Marittima 3
Jinan 3
Monte San Pietro 3
Padova 3
Porto 3
Ypsilanti 3
Ancona 2
Asciano 2
Aulla 2
Binago 2
Bologna 2
Brasília 2
Calenzano 2
Casaleone 2
Castrop-rauxel 2
Chieti 2
Chiswick 2
Cormano 2
Dhaka 2
Duncan 2
Empoli 2
Falkenstein 2
Frosinone 2
Hong Kong 2
Hounslow 2
Jersey City 2
Kilburn 2
Kortrijk 2
Lappeenranta 2
Madrid 2
Mission Viejo 2
Modena 2
Monopoli 2
Munich 2
Málaga 2
Ningbo 2
Northampton 2
Nuremberg 2
Phoenix 2
Rometta Marea 2
Totale 4.719
Salva come PNG Salva come JPEG
Nome #
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 208
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 196
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 185
Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum 176
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 171
Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 49 5 patients with chronic hepatitis C 157
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 153
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 151
Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non‐A, non‐B hepatitis 138
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 133
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients 128
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation 121
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 119
Screening and detecting significant liver fibrosis in patients with NAFLD: A practical approach using non-invasive tests 110
HEPATITIS-C VIRUS - A POSSIBLE CAUSE OF CHRONIC HEPATITIS IN ALCOHOLICS 109
Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? 108
Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels 108
Effect of α‐interferon therapy on hepatitis C viraemia in community‐acquired chronic non‐A, non‐B hepatitis: A quantitative polymerase chain reaction study 107
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 107
HCV INFECTION AND CHRONIC ACTIVE HEPATITIS IN ALCOHOLICS 107
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C 106
Persistent hepatitis C viraemia without liver disease 105
Ribavirin for chronic hepatitis C: And the mystery goes on 105
A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy 105
Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C 103
Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C 101
LONG-TERM PERSISTENCE OF IGM ANTIBODIES TO HCV IN CHRONIC HEPATITIS-C 100
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 99
Primary Biliary cholangitis case-finding: an italian multicenter observational study on patients with incidental finding of anti-mithocondrial antibodies 97
Reactivation of Crohn's disease after pandemic aH1N1 and seasonal flu vaccinations 95
Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C 95
Role of amantadine and other adjuvant therapies in the treatment of hepatitis C 94
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 94
Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?” 94
Severe acute autoimmune hepatitis after natalizumab treatment 93
Spleen stiffness measurements predict the risk of hepatic decompensation after direct-acting antivirals in HCV cirrhotic patients 90
Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C 89
Serological and histological aspects of hepatitis C virus infection in alcoholic patients 89
What hides behind an intention-to-treat analysis? 87
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 83
Proctosigmoidite ulcerosa refrattaria e recidivante alla terapia topica trattata con beclometasone dipropionato orale 79
Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis 78
Cell renewal and cancer risk of the stomach: Analysis of cell proliferation kinetics in atrophic gastritis 77
EFFECT OF LACTOBACILLUS ACIDOPHILUS AND BIFIDOBACTERIUM BIFIDUM ON RECTAL CELL-KINETICS AND FECAL PH 74
Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience 72
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis 70
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis. 64
Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction 62
Whipple's disease with melaena and multiple petechial haemorrhages in duodenal mucosa 57
DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV CIRRHOTIC PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 56
Re-treatment of patients with chronic hepatitis C in clinical practice: Results of a multicenter retrospective survey [Ritrattamento dei pazienti con epatite cronica da HCV nella pratica clinica: Risultati di uno studio multicentrico retrospettivo] 55
Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders 52
Enhanced response to peginterferon-alpha-2a based triple therapy in previously non-responsive chronic hepatitis C: Final results of PRETTY study 49
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 45
RECTAL CELL-PROLIFERATION AND COLON CANCER RISK IN ULCERATIVE-COLITIS 44
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 44
Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: Evidence for long-term efficacy and safety 40
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues—A Delphi Consensus Project 33
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 30
VIROLOGICAL FAILURES TO NEW DIRECT ACTING ANTIVIRALS IN A REAL LIFE SETTING MAY REQUIRE UNCONVENTIONAL REGIMENS FOR RE-TREATMENT 28
Trattamento della Epatite da HCV 27
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 27
Management of Delta Hepatitis 45 years after the discovery of HDV 26
Loss and seroconversion of hepatitis B surface antigen after vaccine therapy in chronic hepatitis B patients treated with nucleoside/nucleotide analogues 26
Prospective evaluation of aberrant p16 methylation in serum of patients before and after therapy for localized HCC 25
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 24
Incidental finding of anti-mitochondrial antibody: a neglected entity needing reappraisal 22
Terapia cellulare in Epatologia 22
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy 22
Prospective study on the prevalence of HCV infection in consecutive adult inpatients in a hospital division of Internal Medicine in Tuscany 22
RIBAVIRIN PRIMING ENHANCES EFFICACY OF CHRONIC HEPATITIS C RE-TREATMENT IN PATIENTS WHO HAD NOT RESPONDED TO PREVIOUS COMBINATION THERAPY 21
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 21
Panel discussion 19
La ribavirina nell'epatite cronica C: storia e segreti di un grande successo 18
The role of gut microbiota in chronic liver diseases 15
null 10
Liver Stiffness Values to Predict Occurrence and Recurrence of Hepatocellular Carcinoma 5
Totale 6.177
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.370
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020887 0 0 0 0 94 128 135 171 127 111 47 74
2020/2021922 33 109 28 122 88 95 41 152 31 107 46 70
2021/2022750 45 68 44 54 28 26 37 37 41 78 92 200
2022/20231.021 89 90 124 158 90 237 10 78 83 4 32 26
2023/2024910 63 57 94 103 43 187 232 17 6 33 16 59
2024/2025381 52 85 166 68 10 0 0 0 0 0 0 0
Totale 6.177